Improving survival during heart transplantation: Diagnosis of antibody-mediated rejection and techniques for the prevention of graft injury

Future Cardiology

Volumn 8, Issue 4, 2012, Pages 623-635

  Patel, Jignesh K ^a   Kobashigawa, Jon A ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

antibodies; antibody mediated rejection; panel reactive antibodies; rejection; sensitization; virtual cross match

Indexed keywords

B CELL ACTIVATING FACTOR; BORTEZOMIB; CD63 ANTIGEN; ECULIZUMAB; EPRATUZUMAB; EVEROLIMUS; IMMUNOGLOBULIN G; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; RANTES; RAPAMYCIN; RITUXIMAB; STEROID; VASCULAR CELL ADHESION MOLECULE 1;

ANTIBODY DETECTION; ANTIBODY MEDIATED REJECTION; ANTIBODY RESPONSE; B LYMPHOCYTE; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CARDIOVASCULAR RISK; COMPLEMENT SYSTEM; DESENSITIZATION; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SPLENECTOMY; T LYMPHOCYTE; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; CELL ADHESION MOLECULES; ENDOTHELIUM, VASCULAR; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSION; ISOANTIBODIES; RISK FACTORS; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 84864835914     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.12.27     Document Type: Review

References (68)

1. Billingham ME. Endomyocardial biopsy detection of acute rejection in cardiac allograft recipients. Heart Vessels Suppl. 1, 86-90 (1985).
2. Subherwal S, Kobashigawa JA, Cogert G, Patel J, Espejo M, Oeser B. Incidence of acute cellular rejection and non-cellular rejection in cardiac transplantation. Transplant. Proc. 36(10), 3171-3172 (2004).
3. Herskowitz A, Soule LM, Ueda K et al. Arteriolar vasculitis on endomyocardial biopsy: A histologic predictor of poor outcome in cyclosporine-treated heart transplant recipients. J. Heart Transplant. 6(3), 127-136 (1987).
4. Hammond E, Yowell R, Nunoda S et al. Vascular (humoral) rejection in heart transplantation: Pathologic observations and clinical implications. J. Heart Lung Transplant. 9(4), 447-449 (1998).
5. Michaels PJ, Espejo ML, Kobashigawa J et al. Humoral rejection in cardiac transplantation: Risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J. Heart Lung Transplant. 22(1), 58-69 (2003).
6. Salomon RN, Hughes CC, Schoen FJ, Payne DD, Pober JS, Libby P. Human coronary transplantation-associated arteriosclerosis. Evidence for a chronic immune reaction to activated graft endothelial cells. Am. J. Pathol. 138(4), 791-798 (1991).
7. Labarrere CA, Pitts D, Nelson DR, Faulk WP. Coronary artery disease in cardiac allografts: Association with arteriolar endothelial HLA-DR and ICAM-1 antigens. Transplant. Proc. 27(3), 1939-1940 (1995).
8. Colvin RB, Smith RN. Antibody-mediated organ-allograft rejection. Nat. Rev. Immunol. 5(10), 807-817 (2005).
9. Baldwin WM 3rd, Kasper EK, Zachary AA, Wasowska BA, Rodriguez ER. Beyond C4d: Other complement-related diagnostic approaches to antibody-mediated rejection. Am. J. Transplant. 4(3), 311-318 (2004).
10. Morrell CN, Murata K, Swaim AM et al. In vivo platelet-endothelial cell interactions in response to major histocompatibility complex alloantibody. Circ. Res. 102(7), 777-785 (2008).
11. Labarrere CA, Nelson DR, Faulk WP. Endothelial activation and development of coronary artery disease in transplanted human hearts. JAMA 278(14), 1169-1175 (1997).
12. Hirohashi T, Chase CM, Della Pelle P et al. A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am. J. Transplant. 12(2), 313-321 (2011).
13. Stewart S, Winters GL, Fishbein MC et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J. Heart Lung Transplant. 24(11), 1710-1720 (2005).
14. Wu GW, Kobashigawa JA, Fishbein MC et al. Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes. J. Heart Lung Transplant. 28(5), 417-422 (2009).
15. Kfoury AG, Hammond ME, Snow GL et al. Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection. J. Heart Lung Transplant. 28(8), 781-784 (2009).
16. Kfoury AG, Hammond ME. Controversies in defining cardiac antibody-mediated rejection: Need for updated criteria. J. Heart Lung Transplant. 29(4), 389-394 (2010).
17. Kobashigawa J, Crespo-Leiro MG, Ensminger SM et al. Report from a consensus conference on antibody-mediated rejection in heart transplantation. J. Heart Lung Transplant. 30(3), 252-269 (2011).
18. Berry GJ, Angelini A, Burke MM et al. The ISHLT working formulation for pathologic diagnosis of antibody-mediated rejection in heart transplantation: Evolution and current status (2005-2011). J. Heart Lung Transplant. 30(6), 601-611 (2011).
19. John R, Lietz K, Schuster M et al. Immunologic sensitization in recipients of left ventricular assist devices. J. Thorac. Cardiovasc. Surg. 125(3), 578-591 (2003).
20. Hammond EH, Yowell RL, Nunoda S et al. Vascular (humoral) rejection in heart transplantation: Pathologic observations and clinical implications. J. Heart Transplant. 8(6), 430-443 (1989).
21. Kfoury AG, Stehlik J, Renlund DG et al. Impact of repetitive episodes of antibody-mediated or cellular rejection on cardiovascular mortality in cardiac transplant recipients: Defining rejection patterns. J. Heart Lung Transplant. 25(11), 1277-1282 (2006).
22. Reed EF, Demetris AJ, Hammond E et al. Acute antibody-mediated rejection of cardiac transplants. J. Heart Lung Transplant. 25(2), 153-159 (2006).
23. Hooper DK, Hawkins JA, Fuller TC, Profaizer T, Shaddy RE. Panel-reactive antibodies late after allograft implantation in children. Ann. Thorac. Surg. 79(2), 641-644; Discussion 645 (2005).
24. John R, Boyle A, Pagani F, Miller L. Physiologic and pathologic changes in patients with continuous-flow ventricular assist devices. J. Cardiovasc. Transl. Res. 2(2), 154-158 (2009).
25. Reed E, Beer AE, Hutcherson H, King DW, Suciu-Foca N. The alloantibody response of pregnant women and its suppression by soluble HLA antigens and anti-idiotypic antibodies. J. Reprod. Immunol. 20(2), 115-128 (1991).
26. Arnaoutakis GJ, George TJ, Kilic A et al. Effect of sensitization in US heart transplant recipients bridged with a ventricular assist device: Update in a modern cohort. J. Thorac. Cardiovasc. Surg. 142(5), 1236.e1-1245.e1, (2011).
27. Massad MG, Cook DJ, Schmitt SK et al. Factors influencing HLA sensitization in implantable LVAD recipients. Ann. Thorac. Surg. 64(4), 1120-1125 (1997).
28. John R, Rajasinghe H, Chen JM et al. Impact of current management practices on early and late death in more than 500 consecutive cardiac transplant recipients. Ann. Surg. 232(3), 302-311 (2000).
29. Drakos SG, Kfoury AG, Kotter JR et al. Prior human leukocyte antigen-allosensitization and left ventricular assist device type affect degree of post-implantation human leukocyte antigen-allosensitization. J. Heart Lung Transplant. 28(8), 838-842 (2009).
30. George I, Colley P, Russo MJ et al. Association of device surface and biomaterials with immunologic sensitization after mechanical support. J. Thorac. Cardiovasc. Surg. 135(6), 1372-1379 (2008).
31. Coppage M, Baker M, Fialkow L et al. Lack of significant De novo HLA allosensitization in ventricular assist device recipients transfused with leukoreduced, ABO identical blood products. Hum. Immunol. 70(6), 413-416 (2009).
32. Nwakanma LU, Williams JA, Weiss ES, Russell SD, Baumgartner WA, Conte JV. Influence of pretransplant panel-reactive antibody on outcomes in 8,160 heart transplant recipients in recent era. Ann. Thorac. Surg. 84(5), 1556-1562; Discussion 1562-1563 (2007).
33. Tinckam KJ, Chandraker A. Mechanisms and role of HLA and non-HLA alloantibodies. Clin. J. Am. Soc. Nephrol. 1(3), 404-414 (2006).
34. Schlaf G, Pollok-Kopp B, Manzke T, Schurat O, Altermann W. Novel solid phase-based ELISA assays contribute to an improved detection of anti-HLA antibodies and to an increased reliability of pre- and post-transplant crossmatching. NDT Plus 3(6), 527-538 (2010).
35. Altermann WW, Seliger B, Sel S, Wendt D, Schlaf G. Comparison of the established standard complement-dependent cytotoxicity and flow cytometric crossmatch assays with a novel ELISA-based HLA crossmatch procedure. Histol. Histopathol. 21(10), 1115-1124 (2006).
36. Smith JD, Hamour IM, Banner NR, Rose ML. C4d fixing, luminex binding antibodies - A new tool for prediction of graft failure after heart transplantation. Am. J. Transplant. 7(12), 2809-2815 (2007).
37. Won DI, Jung HD, Jung OJ, Huh S, Suh JS. Flow cytometry PRA using lymphocyte pools from random donors. Cytometry B. Clin. Cytom. 72(4), 256-264 (2007).
38. El-Awar N, Lee J, Terasaki PI. HLA antibody identification with single antigen beads compared to conventional methods. Hum. Immunol. 66(9), 989-997 (2005).
39. Stehlik J, Islam N, Hurst D et al. Utility of virtual crossmatch in sensitized patients awaiting heart transplantation. J. Heart Lung Transplant. 28(11), 1129-1134 (2009).
40. Zangwill S, Ellis T, Stendahl G, Zahn A, Berger S, Tweddell J. Practical application of the virtual crossmatch. Pediatr. Transplant. 11(6), 650-654 (2007).
41. Kobashigawa J, Mehra M, West L et al. Report from a consensus conference on the sensitized patient awaiting heart transplantation. J. Heart Lung Transplant. 28(3), 213-225 (2009).
42. Pisani BA, Mullen GM, Malinowska K et al. Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. J. Heart Lung Transplant. 18(7), 701-706 (1999).
43. Jordan SC, Toyoda M, Vo AA. Intravenous immunoglobulin a natural regulator of immunity and inflammation. Transplantation 88(1), 1-6 (2009).
44. John R, Lietz K, Burke E et al. Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. Circulation 100(Suppl. 19), II229-II235 (1999).
45. Vo AA, Lukovsky M, Toyoda M et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N. Engl. J. Med. 359(3), 242-251 (2008).
46. Kobashigawa JA, Patel JK, Kittleson MM et al. The long-term outcome of treated sensitized patients who undergo heart transplantation. Clin. Transplant. 25(1), E61-E67 (2011).
47. Perry DK, Burns JM, Pollinger HS et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am. J. Transplant. 9(1), 201-209 (2009).
48. Idica A, Kaneku H, Everly MJ et al. Elimination of post-transplant donor-specific HLA antibodies with bortezomib. Clin. Transpl. 229-239 (2008).
49. Trivedi HL, Terasaki PI, Feroz A et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 87(10), 1555-1561 (2009).
50. Patel J, Everly M, Chang D, Kittleson M, Reed E, Kobashigawa J. Reduction of alloantibodies via proteosome inhibition in cardiac transplantation. J. Heart Lung Transplant. 30(12), 1320-1326 (2011).
51. Takemoto SK, Zeevi A, Feng S et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am. J. Transplant. 4(7), 1033-1041 (2004).
52. Nair N, Ball T, Uber PA, Mehra MR. Current and future challenges in therapy for antibody-mediated rejection. J. Heart Lung Transplant. 30(6), 612-617 (2011).
53. Olsen SL, Wagoner LE, Hammond EH et al. Vascular rejection in heart transplantation: Clinical correlation, treatment options, and future considerations. J. Heart Lung Transplant. 12(2), S135-S142 (1993).
54. Zand MS, Vo T, Huggins J et al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 79(11), 1507-1515 (2005).
55. Bohmig GA, Regele H, Exner M et al. C4d-positive acute humoral renal allograft rejection: Effective treatment by immunoadsorption. J. Am. Soc. Nephrol. 12(11), 2482-2489 (2001).
56. Leech SH, Lopez-Cepero M, Lefor WM et al. Management of the sensitized cardiac recipient: The use of plasmapheresis and intravenous immunoglobulin. Clin. Transplant. 20(4), 476-484 (2006).
57. Garrett HE Jr, Groshart K, Duvall- Seaman D, Combs D, Suggs R. Treatment of humoral rejection with rituximab. Ann. Thorac. Surg. 74(4), 1240-1242 (2002).
58. Baran DA, Lubitz S, Alvi S et al. Refractory humoral cardiac allograft rejection successfully treated with a single dose of rituximab. Transplant. Proc. 36(10), 3164-3166 (2004).
59. Everly MJ, Everly JJ, Susskind B et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 86(12), 1754-1761 (2008).
60. Walsh RC, Everly JJ, Brailey P et al. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation 89(3), 277-284 (2010).
61. Stegall MD, Diwan T, Raghavaiah S et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am. J. Transplant. 11(11), 2405-2413 (2011).
62. Jin YP, Fishbein MC, Said JW et al. Anti-HLA class I antibody-mediated activation of the PI3K/Akt signaling pathway and induction of Bcl-2 and Bcl-xL expression in endothelial cells. Hum. Immunol. 65(4), 291-302 (2004).
63. Jin YP, Jindra PT, Gong KW, Lepin EJ, Reed EF. Anti-HLA class I antibodies activate endothelial cells and promote chronic rejection. Transplantation 79(Suppl. 3), S19-S21 (2005).
64. Jindra PT, Jin YP, Rozengurt E, Reed EF. HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. J. Immunol. 180(4), 2357-2366 (2008).
65. Keogh A, Richardson M, Ruygrok P et al. Sirolimus in De novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: A randomized clinical trial. Circulation 110(17), 2694-2700 (2004).
66. Eisen HJ, Tuzcu EM, Dorent R et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N. Engl. J. Med. 349(9), 847-858 (2003).
67. Kobashigawa JA, Miller LW, Russell SD et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am. J. Transplant. 6(6), 1377-1386 (2006).
68. Warren DS, Zachary AA, Sonnenday CJ et al. Successful renal transplantation across simultaneous ABO incompatible and positive crossmatch barriers. Am. J. Transplant. 4(4), 561-568 (2004).